Royce & Associates’s Diebold Nixdorf DBD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14M Sell
164,965
-2,578
-2% -$207K 0.11% 303
2026
Q1
$12.6M Sell
167,543
-2,764
-2% -$203K 0.12% 265
2025
Q4
$11.6M Sell
170,307
-30,232
-15% -$1.89M 0.12% 264
2025
Q3
$11.4M Sell
200,539
-1,043
-0.5% -$61.8K 0.11% 263
2025
Q2
$11.2M Sell
201,582
-21,026
-9% -$986K 0.11% 259
2025
Q1
$9.73M Sell
222,608
-23,660
-10% -$1.03M 0.11% 291
2024
Q4
$10.6M Buy
246,268
+69,360
+39% +$3.12M 0.1% 300
2024
Q3
$7.9M Buy
+176,908
New +$7.32M 0.07% 370

Other funds holding DBD

Royce & Associates's DBD Position: Q2 2026 in Review

Royce & Associates reduced its Diebold Nixdorf (DBD) stake by 1.5% in Q2 2026, selling an estimated $207K and leaving 164,965 shares worth $14M. The position accounts for 0.11% of the portfolio, ranked #303.

Royce & Associates first reported a position in DBD in Q3 2024 and has held it in 8 quarters since. 216 funds tracked by Wall St. Rank hold DBD as of Q2 2026.

  • Royce & Associates held 164,965 shares of Diebold Nixdorf worth $14M as of Q2 2026.
  • Royce & Associates sold 2,578 Diebold Nixdorf shares in Q2 2026, an estimated $207K.
  • Diebold Nixdorf made up 0.11% of Royce & Associates's portfolio in Q2 2026, its #303 holding.
  • Royce & Associates first reported a position in Diebold Nixdorf in Q3 2024 and has held it in 8 quarters since.
  • 216 funds tracked by Wall St. Rank held Diebold Nixdorf as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.